Rydex Biotechnology Fund Class Investor (RYOIX)

Fund Assets	131.59M
Expense Ratio	1.393%
Min. Investment	$2,500
Turnover	75.00%
Dividend (ttm)	n/a
Dividend Yield	n/a
Dividend Growth	n/a
Payout Frequency	Annual
Ex-Dividend Date	Dec 16, 2025

Previous Close	92.67
YTD Return	26.14%
1-Year Return	37.93%
5-Year Return	47.57%
52-Week Low	72.00
52-Week High	98.74
Beta (5Y)	0.88
Holdings	72
Inception Date	Apr 1, 1998

About RYOIX

Rydex Biotechnology Fund Class Investor is an actively managed mutual fund focused on the biotechnology sector. Its primary objective is to achieve capital appreciation by investing at least 80% of its net assets in equity securities of U.S.-traded biotechnology companies, leveraging both direct equity investments and derivatives such as futures contracts and options. The fund is non-diversified, allowing for a concentrated approach that can include significant positions in small to mid-sized biotechnology firms. This structure enables the fund to target growth opportunities within an industry known for innovation in medical research, pharmaceuticals, and life sciences. Managed by Security Investors, LLC since its inception in 1998, the fund plays a specialized role in the market by providing investors targeted access to biotechnology’s dynamic growth prospects, as well as exposure to the risks and rewards inherent in sector-specific strategies. It distributes capital gains annually and offers a relatively low entry point for individual investors, making it accessible for those seeking focused exposure to biotechnology advancements and trends.

• Fund Family: Rydex Funds
• Category: Health
• Performance Rating: Average
• Risk Rating: Above Average
• Stock Exchange: Nasdaq
• Ticker Symbol: RYOIX
• Share Class: Investor Class
• Index: S&P 500 TR

Performance

RYOIX had a total return of 37.93% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.07%.

Equivalent Funds

These are funds that follow the same index from the other major fund companies.

Symbol	Provider	Name	Expense Ratio
FIKCX	Fidelity	Fidelity Advisor Health Care Z	0.59%
FSPHX	Fidelity	Fidelity Select Health Care Portfolio	0.62%
FIJYX	Fidelity	Fidelity Advisor Biotechnology Z	0.57%
FACDX	Fidelity	Fidelity Advisor Health Care A	0.96%
FSHCX	Fidelity	Fidelity Select Health Care Services Portfolio	0.67%

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
RYBOX	Class A	1.65%
RYOAX	Class H	1.65%
RYCFX	Class C	2.40%

Top 10 Holdings

38.68% of assets

Name	Symbol	Weight
AbbVie Inc.	ABBV	8.47%
Amgen Inc.	AMGN	5.58%
Gilead Sciences, Inc.	GILD	4.81%
Vertex Pharmaceuticals Incorporated	VRTX	4.31%
Regeneron Pharmaceuticals, Inc.	REGN	3.73%
Revolution Medicines, Inc.	RVMD	2.58%
BeOne Medicines AG	ONC	2.50%
Illumina, Inc.	ILMN	2.35%
Royalty Pharma plc	RPRX	2.18%
Natera, Inc.	NTRA	2.17%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 16, 2025	$9.40578	Dec 16, 2025
Dec 12, 2024	$9.42277	Dec 12, 2024
Dec 20, 2022	$0.89943	Dec 20, 2022
Dec 8, 2021	$15.77303	Dec 8, 2021
Dec 9, 2020	$6.95038	Dec 9, 2020
Dec 10, 2019	$3.60206	Dec 10, 2019

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Oct 16, 2026

Data Sources Report a data error